Brief: Promore Pharma Updates On Phase II Clinical Trial With Ensereptide

PMD Device Solutions AB

01/11/2022 09:49

Nov 1 (Reuters) - Promore Pharma AB  PROMO.ST :
    * RESULTS FROM CO'S PHASE II STUDY PHSU05 WITH ENSEREPTIDE
FOR
PREVENTION OF SKIN SCARRING IS EXPECTED TO BE AVAILABLE IN APRIL
2023
    * CLINICAL PART OF TRIAL WAS COMPLETED ACCORDING TO PLAN
EARLIER
THIS YEAR
    * BUT LIMITED AVAILABILITY OF QUALIFIED PERSONNEL,
SPECIALIZED
IMAGE ANALYSIS EQUIPMENT RESULTS IN SLIGHTLY LONGER DURATION OF
HISTOPATHOLOGICAL ANALYSIS THAN EXPECTED

Source text for Eikon:  ID:nMFN5jRctM 
Further company coverage:  PROMO.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))